2 Biotech Giants to Buy in 2026 [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
They set out to tackle some of the most challenging diseases, and as they progress toward the finish line, their stock prices might take off. And once they actually reach their goals and commercialize a product or products, these players should continue to offer you growth, and at the same time, an element of safety -- the idea here is patients need their medications, so revenue may achieve a certain stability. With this in mind, let's check out two biotech giants that have proven themselves with solid pipelines and a number of products on the market. They make great additions to any portfolio in 2026. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. 1. Regeneron Pharmaceuticals Regeneron Pharmaceuticals (NASDAQ: REGN) has two big sources of growth right now: Dupixent, a drug tha
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” [Yahoo! Finance]Yahoo! Finance
- These 5 New York companies are among America's best employers [USA TODAY]USA TODAY
- Regeneron Pharmaceuticals (REGN) had its price target raised by Royal Bank Of Canada from $745.00 to $765.00. They now have a "sector perform" rating on the stock.MarketBeat
- Regeneron's Dupixent Win And Rare Disease Push Reshape Risk Reward Profile [Yahoo! Finance]Yahoo! Finance
- Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- REGN's page on the SEC website